← Back to Analyst Consensus 
ORMP Hold
ORAMED PHARMACEUTICALS INC.
Current Price —
Implied Upside —
Analysts 6
30-Day Momentum
▲ 0 upgrades / ▼ 0 downgrades / 0 reiterations from 0 firms
Next Earnings
Nov 11, 2026 (16 days)
Rating Timeline
| Date ▼ | Firm | Action | From → To Rating | Price Target | Firm Rating |
|---|---|---|---|---|---|
| Sep 9, 2024 | HC Wainwright & Co. | reiterate | — → Neutral | $0 | 44% |
| May 20, 2024 | HC Wainwright & Co. | reiterate | — → Neutral | $0 | 44% |
| May 17, 2023 | Canaccord Genuity | maintain | Hold → Hold | $2 | 48% |
| Jan 17, 2023 | HC Wainwright & Co. | downgrade | Buy → Neutral | $0 | 44% |
| Jan 12, 2023 | Canaccord Genuity | downgrade | Buy → Hold | $0 | 48% |
| May 16, 2022 | Aegis Capital | maintain | — → Buy | $30 | — |
| Feb 18, 2022 | Cantor Fitzgerald | initiate | — → Overweight | $20 | 50% |
| Nov 30, 2021 | HC Wainwright & Co. | maintain | — → Buy | $32 | 44% |
| Nov 29, 2021 | HC Wainwright & Co. | maintain | — → Buy | $32 | 44% |
| Nov 2, 2021 | Aegis Capital | maintain | — → Buy | $35 | — |
| Jul 29, 2021 | Canaccord Genuity | maintain | — → Buy | $30 | 48% |
| Jun 8, 2021 | Aegis Capital | maintain | — → Buy | $20 | — |
| Apr 20, 2021 | Canaccord Genuity | initiate | — → Buy | $27 | 48% |
| Feb 9, 2021 | National Securities Corporation | initiate | — → Buy | $23 | — |
| Jan 27, 2021 | Aegis Capital | maintain | — → Buy | $12 | — |
| Jul 13, 2020 | HC Wainwright & Co. | reiterate | — → Buy | $17 | 44% |
| Jun 22, 2020 | HC Wainwright & Co. | maintain | — → Buy | $16 | 44% |
| Sep 11, 2019 | Ladenburg Thalmann | initiate | — → Buy | $7 | 45% |
| Nov 19, 2015 | FBR Capital | initiate | — → Outperform | $15 | — |
| Oct 1, 2015 | HC Wainwright & Co. | initiate | — → Buy | $24 | 44% |
| Dec 4, 2013 | Aegis Capital | initiate | — → Buy | $25 | — |
Price Target Trend
Mar 31, 2026 Oct 25, 2026
EPS Estimates
0y —
0q —
+1q —
+1y —
Cross-Platform Signals
No cross-platform signals in the last 90 days